Krane Louis S, Heavner Matthew G, Peyton Charles, Rague James T, Hemal Ashok K
Department of Urology, Wake Forest Baptist Health , Winston-Salem, North Carolina.
J Endourol. 2016 May;30(5):532-6. doi: 10.1089/end.2015.0737. Epub 2016 Feb 5.
In patients with normal estimated renal function before robot-assisted partial nephrectomy (RPN), there is still a risk for de Novo chronic kidney disease (CKD). We assessed the role of dipstick spot proteinuria in risk stratifying patients for CKD progression.
From our prospectively maintained, institutional review board-approved database of patients undergoing RPN, we queried those with estimated glomerular filtration rate (eGFR) >60 and bilateral functional units. We assessed proteinuria through dipstick (trace or above) on voided urine in preoperative urologic appointment <3 weeks before RPN. Proteinuric patients were compared with the remainder of the cohort with parametric comparisons for continuous and chi-squared analysis for categoric variables. Multivariate logistic regression analyses were performed assessing the risk of de Novo CKD stage III development, estimated by the CKD-EPI equation.
We found 269 patients with eGFR >60 preoperatively, of whom 57 (21%) had proteinuria preoperatively. In univariate analysis, these patients were more likely to be diabetic (p = 0.023) and to be on an angiotensin converting enzyme inhibitor or angiotensin receptor blocker (p = 0.001) but had similar age (p = 0.13), body mass index (p = 0.09), and tumor size (p = 0.56) with similar rates of hypertension (p = 0.07). At a median 16 months, controlling for confounding variables, preoperative proteinuria on urinary dipstick was associated with a 2.3× (95% confidence interval 1.03-4.95) increased risk of de Novo CKD stage III progression.
Patients with proteinuria preoperatively, despite a normal eGFR, likely have intrinsic medicorenal disease. These patients should be counseled preoperatively that they have a higher risk of CKD progression following RPN.
在机器人辅助部分肾切除术(RPN)前估计肾功能正常的患者中,仍存在发生新发慢性肾脏病(CKD)的风险。我们评估了试纸法检测的随机蛋白尿在CKD进展风险分层中的作用。
从我们前瞻性维护的、经机构审查委员会批准的接受RPN患者数据库中,查询估计肾小球滤过率(eGFR)>60且双侧功能单位的患者。我们在RPN术前<3周的泌尿外科术前检查中,通过试纸法检测晨尿中的蛋白尿(微量或以上)。将蛋白尿患者与队列中的其余患者进行比较,对连续变量进行参数比较,对分类变量进行卡方分析。进行多因素逻辑回归分析,评估根据CKD-EPI方程估计的新发CKD III期进展风险。
我们发现269例术前eGFR>60的患者,其中57例(21%)术前有蛋白尿。在单因素分析中,这些患者更可能患有糖尿病(p = 0.023)且正在使用血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂(p = 0.001),但年龄(p = 0.13)、体重指数(p = 0.09)和肿瘤大小(p = 0.56)相似,高血压发生率也相似(p = 0.07)。在中位随访16个月时,在控制混杂变量后,术前尿试纸法检测到的蛋白尿与新发CKD III期进展风险增加2.3倍(95%置信区间1.03 - 4.95)相关。
术前有蛋白尿的患者,尽管eGFR正常,但可能存在内在的肾内科疾病。术前应告知这些患者,他们在RPN后发生CKD进展的风险更高。